These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18049890)

  • 1. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
    Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
    Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
    Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
    Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
    Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
    Colomer R; Monzo M; Tusquets I; Rifa J; Baena JM; Barnadas A; Calvo L; Carabantes F; Crespo C; Muñoz M; Llombart A; Plazaola A; Artells R; Gilabert M; Lloveras B; Alba E
    Clin Cancer Res; 2008 Feb; 14(3):811-6. PubMed ID: 18245543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
    Akisik E; Dalay N
    Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features.
    Festa-Vasconcellos JS; Piranda DN; Amaral LM; Indio-do-Brasil V; Koifman S; Vianna-Jorge R
    Breast Cancer Res Treat; 2012 Feb; 132(1):251-8. PubMed ID: 22037828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
    Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
    Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis.
    Chhabra A; Fernando H; Watkins G; Mansel RE; Jiang WG
    Oncol Rep; 2007 Oct; 18(4):953-8. PubMed ID: 17786359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
    Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.
    Krupa R; Sliwinski T; Morawiec Z; Pawlowska E; Zadrozny M; Blasiak J
    Exp Oncol; 2009 Dec; 31(4):250-1. PubMed ID: 20010525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    Miron L; Negură L; Peptanariu D; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease.
    Araújo AP; Ribeiro R; Pinto D; Pereira D; Sousa B; Mauricio J; Lopes C; Medeiros R
    DNA Cell Biol; 2009 May; 28(5):265-9. PubMed ID: 19388850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study.
    Espinosa E; Vara JA; Redondo A; Sánchez JJ; Hardisson D; Zamora P; Pastrana FG; Cejas P; Martínez B; Suárez A; Calero F; Barón MG
    J Clin Oncol; 2005 Oct; 23(29):7278-85. PubMed ID: 16129846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage.
    Cupisti S; Fasching PA; Ekici AB; Strissel PL; Loehberg CR; Strick R; Engel J; Dittrich R; Beckmann MW; Goecke TW
    Arch Gynecol Obstet; 2009 Sep; 280(3):395-400. PubMed ID: 19152063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients.
    Licznerska BE; Wegman PP; Nordenskjöld B; Wingren S
    Breast Cancer Res Treat; 2008 Nov; 112(1):15-23. PubMed ID: 18030614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.
    Boyapati SM; Shu XO; Ruan ZX; Cai Q; Smith JR; Wen W; Gao YT; Zheng W
    Clin Cancer Res; 2005 Feb; 11(3):1093-8. PubMed ID: 15709176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.